Has JNJ Finally Moved Past Its Quality-Control Woes?

Johnson & Johnson is throwing off billions of dollars to settle quality-control cases, but has Alex Gorsky ensured the worst is over for JNJ? More 

These 48 Blue Chips Are On the Move

It's time to review or gradings for 48 Blue Chip stocks in our portfolio More 

Buy These 3 Stocks for a Monthly Paycheck

Investors with an extra-close eye on regular retirement income can secure themselves a monthly paycheck by bundling trios of dividend stocks. More 

Biotech Blowout: 3 Stocks Taking a Hit

The risky side of biotech stocks reared its ugly head in the past couple of days, sending three stocks to the mat in the wake of bad news. More 

Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons

GlaxoSmithKline is seeking approval for the world's first malaria vaccine, but high debt and low growth mean investors should think twice before buying. More 

One Lonely IPO On Deck for the Week

We take a look a look at the lone IPO slated to go live this week -- OCI Resources -- as well as four companies that will go public next week. More 

Bull’s Eye Report: Gilead Sciences (GILD)

Despite its recent runup, Gilead Sciences (GILD) shows room for immediate upside. More